Gsk Plc ADR (GSK)

$43.35 -0.34 (-0.78%)
Market Cap 88.88B
Revenue (ttm) 40.10B
Net Income (ttm) 3.29B
EPS (ttm) N/A
PE Ratio 10.78
Forward PE 10.35
Profit Margin 8.21%
Debt to Equity Ratio 1.21
Volume 13,115,700
Avg Vol 4,644,054
Day's Range N/A - N/A
Shares Out 2.03B
Stochastic %K 64%
Beta 0.53
Analysts Hold
Price Target $39.39

Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephr...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 8047 5000
Website: www.gsk.com
Address:
79 New Oxford Street, London, United Kingdom
Vikingsstrade
Vikingsstrade Oct. 3 at 5:05 PM
$REAX $FGNX $GSK $FSLY Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
Quantumup
Quantumup Oct. 3 at 4:27 PM
$DAWN's Chief Development Officer Davy Chiodin Will Join the FDA & Osteosarcoma Institute Workshop, Advancing Osteosarcoma Drug Development – Connecting Research and Regulatory Pathways for Improved Outcomes on Oct 10, 2025 at 3:00-4:00 PM. $AZN $GSK $EXEL https://fda.gov/news-events/fda-meetings-conferences-and-workshops/fdathe-osteosarcoma-institute-osi-workshop-advancing-osteosarcoma-drug-development-connecting SESSION 7: The Path Forward • How advocacy, academic, industry, and regulatory parties can collaborate on a path forward through specific product development, trial design, endpoints, combination, and platform trials. Panelists will discuss opportunities for advocacy, academia, industry and regulatory parties to collaborate on a path forward to advance osteosarcoma drug development, improve trial design, and drive better outcomes for patients. https://www.linkedin.com/company/dayonebio/posts/
0 · Reply
Okadarlan
Okadarlan Oct. 2 at 11:20 PM
$GSK great opportunities.
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 5:32 PM
$GSK: Unusual Options Activity Alerted CALL flow observed 200x contracts at Strike price of $46 Exp on 11/21/2025 with Premium of $36K and showing BULLISH Sentiment
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 4:03 PM
$GSK: Unusual Options Activity Alerted CALL flow observed 75x contracts at Strike price of $40 Exp on 06/18/2026 with Premium of $28K and showing BULLISH Sentiment
0 · Reply
BinaryLogic
BinaryLogic Oct. 2 at 12:42 AM
$PFE Look at the 1YR Daily, and you will see a consistent resistant/support line at $27.3 (appx). The Company is trading at a 1.7 BV and NTM P/E ~ 9.7. This stock literally has 50-100% upside from this level (IMO). Good/consistent revenue, EBITDA~38%, positive FCF, good liquidity and balanced capital structure - 7.2% Dividend Yield. Growth and Income. Watch large and small bio-pharma (hopefully) for a Bullish cycle/progression. $MRK $BMY $GSK $LLY
0 · Reply
cubie
cubie Oct. 1 at 6:10 PM
$LLY $PFE $MRK $GSK $REGN people cannot be this stupid, but never underestimate stupidty of noobtards like you smh
0 · Reply
Magnificient
Magnificient Oct. 1 at 6:08 PM
$LLY $PFE $MRK $GSK $REGN im Listening to a Eli Lilly call Masterclass Obesity Woman. After that i will understand you better. Wait 19 min
1 · Reply
cubie
cubie Oct. 1 at 6:04 PM
$LLY $PFE $MRK $GSK $REGN are u serious? u been in a cave?
0 · Reply
Gramma
Gramma Oct. 1 at 5:48 PM
$GSK How about making trelegy less expensive! Costs my husband about 350 a month
0 · Reply
Latest News on GSK
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level

Oct 1, 2025, 10:00 AM EDT - 3 days ago

New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Oct 1, 2025, 7:58 AM EDT - 3 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

BMY XRAY

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026

Sep 29, 2025, 10:00 AM EDT - 5 days ago

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026

GSK turns to insider to be next CEO — and the stock rallies

Sep 29, 2025, 4:46 AM EDT - 5 days ago

GSK turns to insider to be next CEO — and the stock rallies

Who is GSK's next CEO Luke Miels?

Sep 29, 2025, 4:20 AM EDT - 5 days ago

Who is GSK's next CEO Luke Miels?

GSK names Luke Miels as next CEO after Emma Walmsley steps down; shares jump

Sep 29, 2025, 3:59 AM EDT - 5 days ago

GSK names Luke Miels as next CEO after Emma Walmsley steps down; shares jump

GSK names Luke Miels as CEO designate

Sep 29, 2025, 2:07 AM EDT - 5 days ago

GSK names Luke Miels as CEO designate

GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 24, 2025, 9:43 AM EDT - 10 days ago

GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript

Pi Health to Collaborate with GSK to Enhance Clinical Research Services

Sep 24, 2025, 7:45 AM EDT - 10 days ago

Pi Health to Collaborate with GSK to Enhance Clinical Research Services

GSK to submit label update for Leucovorin at FDA's request, does not intend to market it for autism

Sep 22, 2025, 6:20 PM EDT - 12 days ago

GSK to submit label update for Leucovorin at FDA's request, does not intend to market it for autism

FDA approves drug that Trump due to suggest as autism treatment

Sep 22, 2025, 4:55 PM EDT - 12 days ago

FDA approves drug that Trump due to suggest as autism treatment

UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit

Sep 17, 2025, 2:29 AM EDT - 17 days ago

UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit

GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs

Sep 16, 2025, 8:00 PM EDT - 18 days ago

GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs

LLY

GSK plans $30 billion US investment as pharma tariff threat looms

Sep 16, 2025, 7:08 PM EDT - 18 days ago

GSK plans $30 billion US investment as pharma tariff threat looms

GSK Says It Will Spend $30B on U.S. Manufacturing and R&D

Sep 16, 2025, 7:01 PM EDT - 18 days ago

GSK Says It Will Spend $30B on U.S. Manufacturing and R&D

Dividend Income Summary: Lanny's July 2025 Summary

Sep 15, 2025, 7:44 AM EDT - 19 days ago

Dividend Income Summary: Lanny's July 2025 Summary

BNL BNS CM CSCO IRM ITW LEG

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

Sep 10, 2025, 1:03 PM EDT - 24 days ago

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

ABBV AZN NVO NVS SNY AMGN LLY

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

Sep 3, 2025, 1:28 PM EDT - 4 weeks ago

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

WVE

Dynavax's shingles vaccine shows similar immune response to GSK's shot in study

Aug 21, 2025, 8:22 AM EDT - 6 weeks ago

Dynavax's shingles vaccine shows similar immune response to GSK's shot in study

DVAX

GSK's antibiotic drug gepotidacin gets priority review by FDA

Aug 11, 2025, 2:15 AM EDT - 7 weeks ago

GSK's antibiotic drug gepotidacin gets priority review by FDA

GSK to Receive $370 Million in U.S. Patent Litigation Settlement

Aug 8, 2025, 3:31 AM EDT - 2 months ago

GSK to Receive $370 Million in U.S. Patent Litigation Settlement

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Aug 1, 2025, 12:01 PM EDT - 2 months ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AMGN AZN BMY GILD JNJ LLY

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

Jul 31, 2025, 3:35 PM EDT - 2 months ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN BMY GILD JNJ LLY

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

Jul 31, 2025, 3:00 PM EDT - 2 months ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN BMY GILD JNJ LLY

Trump pressures 17 pharma CEOs to cut US drug prices

Jul 31, 2025, 2:28 PM EDT - 2 months ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN BMY GILD JNJ LLY

Trump posts letters to 17 pharmaceutical companies about drug prices

Jul 31, 2025, 2:19 PM EDT - 2 months ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV GILD LLY PFE AMGN AZN BMY

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

Jul 31, 2025, 1:48 PM EDT - 2 months ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AMGN AZN BMY GILD JNJ LLY

GSK plc (GSK) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 5:56 PM EDT - 2 months ago

GSK plc (GSK) Q2 2025 Earnings Call Transcript

GSK CEO: Innovation is the secret to bringing down cost of overall healthcare

Jul 30, 2025, 11:32 AM EDT - 2 months ago

GSK CEO: Innovation is the secret to bringing down cost of overall healthcare

GSK in talks with Trump administration on U.S. drug pricing, CEO says

Jul 30, 2025, 5:26 AM EDT - 2 months ago

GSK in talks with Trump administration on U.S. drug pricing, CEO says

GSK expects annual sales and profit at top end of forecast range

Jul 30, 2025, 2:12 AM EDT - 2 months ago

GSK expects annual sales and profit at top end of forecast range

GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval

Jul 28, 2025, 12:41 PM EDT - 2 months ago

GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval

Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal

Jul 27, 2025, 10:35 PM EDT - 2 months ago

Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

Jul 27, 2025, 9:53 PM EDT - 2 months ago

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

GSK's blood cancer drug gets EU approval for multiple myeloma

Jul 24, 2025, 12:27 PM EDT - 2 months ago

GSK's blood cancer drug gets EU approval for multiple myeloma

GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults

Jul 24, 2025, 9:00 AM EDT - 2 months ago

GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults

US FDA extends review of GSK's blood cancer drug

Jul 23, 2025, 12:15 PM EDT - 2 months ago

US FDA extends review of GSK's blood cancer drug

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

Jul 18, 2025, 8:44 AM EDT - 2 months ago

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

GSK shares fall after blood cancer drug likely headed for U.S. rejection

Jul 18, 2025, 3:24 AM EDT - 2 months ago

GSK shares fall after blood cancer drug likely headed for U.S. rejection

FDA Committee Votes Against GSK Blood Cancer Drug Blenrep

Jul 17, 2025, 6:19 PM EDT - 2 months ago

FDA Committee Votes Against GSK Blood Cancer Drug Blenrep

GSK's Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

Jul 17, 2025, 1:00 PM EDT - 2 months ago

GSK's Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

FDA advisers vote against combination therapies of GSK's blood cancer drug

Jul 17, 2025, 12:53 PM EDT - 2 months ago

FDA advisers vote against combination therapies of GSK's blood cancer drug

US FDA approves pre-filled version of GSK's shingles vaccine

Jul 17, 2025, 7:35 AM EDT - 2 months ago

US FDA approves pre-filled version of GSK's shingles vaccine

US FDA Approves GSK's SHINGRIX in a Prefilled Syringe Presentation

Jul 17, 2025, 7:00 AM EDT - 2 months ago

US FDA Approves GSK's SHINGRIX in a Prefilled Syringe Presentation

Vikingsstrade
Vikingsstrade Oct. 3 at 5:05 PM
$REAX $FGNX $GSK $FSLY Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
Quantumup
Quantumup Oct. 3 at 4:27 PM
$DAWN's Chief Development Officer Davy Chiodin Will Join the FDA & Osteosarcoma Institute Workshop, Advancing Osteosarcoma Drug Development – Connecting Research and Regulatory Pathways for Improved Outcomes on Oct 10, 2025 at 3:00-4:00 PM. $AZN $GSK $EXEL https://fda.gov/news-events/fda-meetings-conferences-and-workshops/fdathe-osteosarcoma-institute-osi-workshop-advancing-osteosarcoma-drug-development-connecting SESSION 7: The Path Forward • How advocacy, academic, industry, and regulatory parties can collaborate on a path forward through specific product development, trial design, endpoints, combination, and platform trials. Panelists will discuss opportunities for advocacy, academia, industry and regulatory parties to collaborate on a path forward to advance osteosarcoma drug development, improve trial design, and drive better outcomes for patients. https://www.linkedin.com/company/dayonebio/posts/
0 · Reply
Okadarlan
Okadarlan Oct. 2 at 11:20 PM
$GSK great opportunities.
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 5:32 PM
$GSK: Unusual Options Activity Alerted CALL flow observed 200x contracts at Strike price of $46 Exp on 11/21/2025 with Premium of $36K and showing BULLISH Sentiment
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 4:03 PM
$GSK: Unusual Options Activity Alerted CALL flow observed 75x contracts at Strike price of $40 Exp on 06/18/2026 with Premium of $28K and showing BULLISH Sentiment
0 · Reply
BinaryLogic
BinaryLogic Oct. 2 at 12:42 AM
$PFE Look at the 1YR Daily, and you will see a consistent resistant/support line at $27.3 (appx). The Company is trading at a 1.7 BV and NTM P/E ~ 9.7. This stock literally has 50-100% upside from this level (IMO). Good/consistent revenue, EBITDA~38%, positive FCF, good liquidity and balanced capital structure - 7.2% Dividend Yield. Growth and Income. Watch large and small bio-pharma (hopefully) for a Bullish cycle/progression. $MRK $BMY $GSK $LLY
0 · Reply
cubie
cubie Oct. 1 at 6:10 PM
$LLY $PFE $MRK $GSK $REGN people cannot be this stupid, but never underestimate stupidty of noobtards like you smh
0 · Reply
Magnificient
Magnificient Oct. 1 at 6:08 PM
$LLY $PFE $MRK $GSK $REGN im Listening to a Eli Lilly call Masterclass Obesity Woman. After that i will understand you better. Wait 19 min
1 · Reply
cubie
cubie Oct. 1 at 6:04 PM
$LLY $PFE $MRK $GSK $REGN are u serious? u been in a cave?
0 · Reply
Gramma
Gramma Oct. 1 at 5:48 PM
$GSK How about making trelegy less expensive! Costs my husband about 350 a month
0 · Reply
Noneyabizness
Noneyabizness Oct. 1 at 5:07 PM
$NVDA $TSM $LLY $GSK $PFE follow the money! Big moves yesterday and today
0 · Reply
lextrading
lextrading Oct. 1 at 2:52 PM
$GSK It's a breakout. Hopefully if can stay above the resistance.
0 · Reply
cubie
cubie Oct. 1 at 1:53 PM
$MRK$PFE $GSK congrats those eho bought calls for day 2 😬
0 · Reply
notreload_ai
notreload_ai Oct. 1 at 12:06 PM
$AZN, $SNY, $GSK ... Pfizer avoided US tariffs by offering big drug discounts (TrumpRx). This deal is a blueprint. European drug stocks (AstraZeneca, Roche) surged hoping for similar agreements to protect their crucial sales from Trump's 100% import tax threat. https://notreload.xyz/european-drugmakers-gain-us-pricing-deals/
0 · Reply
Stock_Savage
Stock_Savage Oct. 1 at 12:40 AM
$PFE $GSK $CURE Gonna hold these 3 for a bit
2 · Reply
PopPortfolios
PopPortfolios Sep. 30 at 7:37 PM
$PFE $GSK about time ... Have been beaten down for a while.. still got a lot more to come. PFE trump deal hopefully will bring some much needed inflow into the sector.
0 · Reply
cubie
cubie Sep. 30 at 6:57 PM
$LLY $GSK $PFE $MRK $XLV trumprx.gov 😅🫢
2 · Reply
clan
clan Sep. 30 at 6:46 PM
$MNKD $GSK $NOV $TAK $MRK This re-manufactured Clofazimine in inhalation form(s) is going to be HUGE for MannKind! Oct. 2025 publication in the Journal Of Pharmaceutical Sciences -- link --> Pulmonary drug delivery of clofazimine: A route of administration and pharmacokinetics guided repositioning strategy against drug resistant tuberculosis informed by use for other disease indications - ScienceDirect https://share.google/PQ72yMfXnstl0IBax
0 · Reply
Jim123456
Jim123456 Sep. 30 at 6:36 PM
$GSK It will soon pull back to $42.3
0 · Reply
SanKish
SanKish Sep. 30 at 5:23 PM
$PFE $BMY $GSK a big Green day finally.
0 · Reply
SnapCrackleStop
SnapCrackleStop Sep. 30 at 4:47 PM
$SCYX If $GSK pays the contrsctural milestone payment of $10MILL that would defiantly help. Till then. Some one call 9-1-1 $
1 · Reply
Jim123456
Jim123456 Sep. 30 at 3:40 PM
$GSK
0 · Reply